An In Vitro Evaluation of a New Approach in AMD: Effects of the Combination of Resveratrol and Anti-VEGFs on ARPE-19 Cells [PDF]
BiomoleculesAnti-vascular endothelial growth factor agents (anti-VEGFs) are the cornerstone of treatment for neovascular age-related macular degeneration (AMD). Resveratrol is a natural polyphenol with well-established antioxidant and anti-apoptotic properties. This
Onur Konukcu +6 more
doaj +2 more sources
Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept [PDF]
Clinical Ophthalmology, 2019 Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon; 3Medical School, Medical ...
Mansour AM, El Jawhari K, Arevalo JF
doaj +2 more sources
Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study. [PDF]
PLoS ONE, 2019 AIM:To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. DESIGN:Prospective, randomised, double blind, interventional study.
Imoro Zeba Braimah +5 more
doaj +2 more sources
Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane [PDF]
Case Reports in Ophthalmological Medicine, 2017 Purpose. To study the effect and outcome of intravitreal Ziv-Aflibercept (IVZ) in treatment of Chronic Central Serous Chorioretinopathy (CSCR) related Choroidal Neovascular Membrane (CNVM). Methods.
Nishant Radke +3 more
doaj +2 more sources
Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) [PDF]
Frontiers in Oncology, 2019 Background: The prognosis of patients with metastatic colorectal cancer (mCRC) is poor, especially after failure of initial systemic therapy. The VELOUR study showed modestly prolonged overall survival (OS) with ziv-aflibercept plus 5-fluorouracil ...
Wafik S. El-Deiry +8 more
doaj +2 more sources
Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. [PDF]
Eye (Lond), 2022 To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and ...
Braimah IZ, Amoaku WM.
europepmc +3 more sources
Osteonecrosis of the jaw associated with ziv-aflibercept. [PDF]
J Gastrointest Oncol, 2016 Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors.
Mawardi H +6 more
europepmc +4 more sources
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment [PDF]
Cancer Immunology, ImmunotherapyF Stephen Hódi +2 more
exaly +2 more sources
Ziv-aflibercept in macular disease. [PDF]
Br J Ophthalmol, 2015 Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept.
Mansour AM +3 more
europepmc +4 more sources
Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy [PDF]
Indian Journal of Ophthalmology, 2019 Kumar Anshuman, Dhanashree Ratra
doaj +2 more sources